Prior to joining Biofortuna, Nick was CEO of Source BioScience plc, the Main Market-listed healthcare diagnostics and genomic services business, where he established operations in the US and Europe, growing revenues five fold.
Nick holds a PhD in Mycology and is a Chartered Accountant, qualifying with KPMG. Nick is also Chairman of Epistem Limited, the pre-clinical and clinical development CRO.
Prior to joining Biofortuna, Nick was COO of Source BioScience plc, expanding the laboratory infrastructure from a single site in the UK to ten facilities worldwide. Before Source BioScience, Nick worked for over ten years in complex genetics and genomics, initially at Oxford University and then for the MRC at the Wellcome Trust Sanger Centre, subsequently Geneservice.
Nick qualified as a microbiologist and worked in the NHS, completing a PhD on the molecular methods used to characterise outbreaks of bacterial meningitis.
David holds a Masters Degree in Mechanical Engineering from Nottingham University and is a chartered accountant, having qualified with Grant Thornton in 2007.